Quest Diagnostics has secured CE Marking for its Simplexa C. difficile Universal Direct test and has launched it in Europe.

The test, marketed by the company's Focus Diagnostics division and developed for the 3M Integrated Cycler, can process up to 94 patient specimens in about an hour, Quest said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.